I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. BeiGene, a Beijing company ...
-
-
Recent Updates
- China’s Fibocom Pitches Cat M Module as a Buffer against Memory Supply Risk
- AlphaPai Takes China AI Investment Research Platform to Global Markets
- China AI Stocks Slide as Nvidia Upheaval Revives US Chip Fears
- China Chip Links Deepen Scrutiny of Alice Huang and Nvidia Figure Jensen Huang
- Nvidia Scandal Deepens as China Links Raise Questions About Alice Huang
- Nvidia China Scandal Pulls Trump Administration Into Congressional Crossfire
- China Based BEST Group Expands Southeast Asia Warehousing for Local Fulfillment
- China’s Guzhen Lighting Fair Plans Six Exhibition Push for 2027 Trade Cycle
- Jensen Huang Resignation Puts Nvidia Under China Scrutiny in Washington
- China APEC Meetings in Shenzhen Add Hollyland as Official Sponsor
Blogroll